176975-26-1

Basic information

• Product Name: Izonsteride
• Synonyms: Izonsteride;(4aR,10bR)-8-(4-Ethylbenzothiazol-2-ylsulfanyl)-4,10b-dimethyl-1,2,3,4,4a,5,6,10b-octahydrobenzo[f]quinolin-3-one;(4aR,10bR)-8-[(4-Ethyl-2-benzothiazolyl)thio]-1,4,4a,5,6,10b-hexahydro-4,10b-dimethylbenzo[f]quinolin-3(2H)-one
• CAS NO: 176975-26-1
• Molecular Formula: C24H26N2OS2
• Molecular Weight: 422.60604
• Mol File: 176975-26-1.mol

Chemical Properties

• Boiling Point: 608.6°C at 760 mmHg
• Flash Point: 321.9°C
• Appearance: /
• Density: 1.29g/cm³
• Vapor Pressure: 9.33E-15mmHg at 25°C
• Refractive Index: 1.686
• CAS DataBase Reference: Izonsteride(CAS DataBase Reference)
• NIST Chemistry Reference: Izonsteride(176975-26-1)
• EPA Substance Registry System: Izonsteride(176975-26-1)

Safety Data

• Hazardous Substances Data: 176975-26-1(Hazardous Substances Data)

Usage

Uses

Treatment of prostate cancer (inhibits human type I and II isoforms of 5 -reductase) .

InChI:InChI=1/C24H26N2OS2/c1-4-15-6-5-7-19-22(15)25-23(29-19)28-17-9-10-18-16(14-17)8-11-20-24(18,2)13-12-21(27)26(20)3/h5-7,9-10,14,20H,4,8,11-13H2,1-3H3/t20-,24-/m1/s1

Upstream product

• 64741-01-1 m-chloroperoxybenzoic acid 
• 176976-44-6 2-chloro-4-ethyl-benzothiazole 
• 1634-04-4 tert-butyl methyl ether 
• 176976-31-1 (+)-(4aR)-(10bR)-4-methyl-8-mercapto-10b-methyl-1,2,3,4,4a,-5,6,10b-octahydrobenzo[f]quinolin-3-one 

Relevant articles and documents

Process for the preparation of benzo[f]quinolinone derivatives and intermediates

The present invention provides a novel process for preparing benzo(f)quinolinones of the formula I wherein R1 represents: 2-nitrophenyl, 4-nitrophenyl, 2-cyanophenyl, 4-cyanophenyl, 2-nitronaphthyl, 4-nitronaphthyl, 2-cyanonaphthyl, 4-cyanonaphthyl, 2-quinolinyl, 4-quinolinyl, 7-quinolinyl, 1-isoquinolinyl, 3-isoquinolinyl, 8-isoquinolinyl, 2-quinoxalinyl, 2-benzothiazolyl, 3-1H-indazolyl, 2-benzoxazolyl, 3-1,2-benzoisothiazolyl, 2-pyridinyl, 4-pyridinyl, 2-pyrazinyl, 2-naphtho[2,3-d]thiazolyl, 2-naphtho[1,2-d]thiazolyl, 9-anthryl, 2-thiazolyl, 2-benzimidazolyl, 1-benz[g]isoquinolinyl, 8-benz[g]isoquinolinyl, 5-1H-tetrazolyl, 2-quinazolinyl, 2-thiazolo[4,5-b]pyridinyl, 4-10H-pyridazino[3,2-b]-2-quinazolinyl, 2-1,4-benzodioxinyl, 2-triazine, 2-benzoxazine, 4-benzoxazine, 2-purine or 8-purine; wherein the above R1 groups are unsubstituted or substituted; and the intermediates of the formulae A,B,C and D.

Synthesis of benzo[f]quinolinones

PCT No. PCT/US97/19229 Sec. 371 Date Mar. 12, 1999 Sec. 102(e) Date Mar. 12, 1999 PCT Filed Oct. 27, 1997 PCT Pub. No. WO98/18757 PCT Pub. Date May 7, 1998A process for preparing intermediates and benzoquinolin-3-one pharmaceuticals, such pharmaceuticals are effective in treating conditions consequent on 5 alpha -reductase.

Method of preventing prostatic cancer development

A series of benzoquinolin-3-ones are pharmaceuticals effective in preventing the development of prostatic cancer, or preventing or treating the metastasis to bone of prostatic cancer.

Methods for inhibiting bone loss

The present invention provides methods of inhibiting bone loss in mammals via the administration to a mammal in need of such treatment an effective amount of a compound from a series of benzoquinolin-3-ones. Such compounds also are sequentially or concurrently coadministered with a bone antiresorptive agent or a bone anabolic agent.

Process for preparation of benzo[f]quinolinones

A series of benzoquinolin-3-ones are pharmaceuticals effective in treating conditions consequent on both Type I and Type II 5α-reductase and their preparation is disclosed.